JP7164596B2 - 抗cd3抗体とその作製及び使用方法 - Google Patents
抗cd3抗体とその作製及び使用方法 Download PDFInfo
- Publication number
- JP7164596B2 JP7164596B2 JP2020511453A JP2020511453A JP7164596B2 JP 7164596 B2 JP7164596 B2 JP 7164596B2 JP 2020511453 A JP2020511453 A JP 2020511453A JP 2020511453 A JP2020511453 A JP 2020511453A JP 7164596 B2 JP7164596 B2 JP 7164596B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- binding fragment
- antibody
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
一実施形態では、パーセンテージ相同性は、70%、75%、80%、90%、95%、98%、又は99%以上である。
一実施形態では、生物学的活性剤は、カペシタビン、シスプラチン、トラスツズマブ、フルベストラント、タモキシフェン、レトロゾール、エキセメスタン、アナストロゾール、アミノグルテチミド、テストラクトン、ボロゾール、フォルメスタン、ファドロゾール、レトロゾール、エルロチニブ、ラファチニブ、ダサチニブ、ゲフィチニブ、イマチニブ、パゾピニブ、ラパチニブ、スニチニブ、ニロチニブ、ソラフェニブ、ナブ-パリタキセル、カリケアマイシン、抗有糸分裂剤、モノメチルオーリスタチンE、エムタンシン、オゾガマイシン、又はそれらの誘導体もしくは組み合わせであってもよい。
ヒトCD3に対するモノクローナル抗体を、ニュージーランドシロウサギを免疫することにより作製した。完全又は不完全フロイントのアジュバント(コホート1)又はTitermax Gold(コホート2)とアルヒドロゲル2%(アルム)プラスCpG 2007を交互に1:1 v/vで混合した、組換えヒトCD3デルタ-エプシロンFc("Knobs-into-hole" - KnH)及びガンマ-エプシロンFc(KnH)融合蛋白質、又はヒト又はカニクイザル"CD3複合体"を一過性トランスフェクションしたHEK 293細胞を動物に皮下注射で免疫した。その後のブーストは、51日目(コホート1)又は68日目(コホート2)まで7日ごとに行った。
1.ヒトCD3デルタ、ガンマ、又はイプシロンFc融合蛋白質への結合 - デルタ、ガンマ、又はイプシロン特異的IgGの検出(ELISA)。
2. カニクイザルCD3デルタ、ガンマ、又はイプシロンFc融合蛋白質への結合 - デルタ、ガンマ、又はイプシロン特異的IgGの検出(ELISA)。
3. ヒトIgGへの結合 - ヒトIgG Fc特異的IgGの検出のためのカウンタースクリーン(ELISA)。
4. ヒトT細胞株Jurkatへの結合 - CD3デルタ、ガンマ、又はイプシロンに特異的なIgGの検出(FACS)。
5. カニクイザルT細胞株HSC-Fへの結合 - CD3デルタ、ガンマ、又はイプシロンに特異的なIgGの検出(FACS)。
6. 非トランスフェクションヒト胚性腎臓(HEK)293細胞への結合 - ヒト又はカニクイザルのCD3デルタ、ガンマ、イプシロンを発現していない細胞での未知の標的に特異的なIgGの検出のためのカウンタースクリーン。
7. 精製ヒトCD3+ T細胞の活性化 - IL-2分泌の検出(ELISA)。
配列番号1
284A10キメラ軽鎖全長核酸配列
GATGTCGTGATGACCCAGACTCCTCCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAAGTGCCAGGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGTGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGCACCGAGGTGGAGTTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号2
284A10キメラ軽鎖可変軽鎖核酸配列
GATGTCGTGATGACCCAGACTCCTCCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAAGTGCCAGGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGTGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGCACCGAGGTGGAGTTCAAA
配列番号3
284A10キメラ軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQTPPSVSAAVGGTVTIKCQASESISSWLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRTYVNSFGGGTEVEFKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号4
284A10キメラ軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQTPPSVSAAVGGTVTIKCQASESISSWLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRTYVNSFGGGTEVEFK
配列番号5
284A10キメラ重鎖全長核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACGCCCCTGACACTCACCTGCACAGTCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGTTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCCAGGCACCCTCGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号6
284A10キメラ重鎖可変重鎖核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACGCCCCTGACACTCACCTGCACAGTCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGTTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCCAGGCACCCTCGTCACCGTCTCGAGC
配列番号7
284A10キメラ重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGFTISTNAMSWVRQVPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSNNIWGPGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号8
284A10キメラ重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGFTISTNAMSWVRQVPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSNNIWGPGTLVTVSS
配列番号9
299F6キメラ軽鎖全長核酸配列
GATGTCGTGATGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTAGTTATGTGAATGCTTTCGGCGGAGGGACCGAGGTGGGGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号10
299F6キメラ軽鎖可変軽鎖核酸配列
GATGTCGTGATGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTAGTTATGTGAATGCTTTCGGCGGAGGGACCGAGGTGGGGGTCAAA
配列番号11
299F6キメラ軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQTPSSVSAAVGGTVTINCQASESISSWLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRSYVNAFGGGTEVVFKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号12
299F6キメラ軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQTPSSVSAAVGGTVTINCQASESISSWLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRSYVNAFGGGTEVVFK
配列番号13
299F6キメラ重鎖全長核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACGCCCCTGACACTCACCTGCACAGTCTCTGGATTCACCATCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAACTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCCAGGGACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号14
299F6キメラ重鎖可変重鎖核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACGCCCCTGACACTCACCTGCACAGTCTCTGGATTCACCATCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAACTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCCAGGGACCCTGGTCACCGTCTCGAGC
配列番号15
299F6キメラ重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGFTISSNAMSWVRQAPGKGLEWIGVITGRDITYYANWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSNNIWGPGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号16
299F6キメラ重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGFTISSNAMSWVRQAPGKGLEWIGVITGRDITYYANWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSNNIWGPGTLVTVSS
配列番号17
480C8キメラ軽鎖全長核酸配列
GATGTCGTGATGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATGCTTTCGGCGGAGGGACCGAGGTGGAGTTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号18
480C8キメラ軽鎖可変軽鎖核酸配列
GATGTCGTGATGACCCAGACTCCATCCTCCGTGTCTGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATGCTTTCGGCGGAGGGACCGAGGTGGAGTTCAAA
配列番号19
480C8キメラ軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQTPSSVSAAVGGTVTINCQASESISSWLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRTYVNAFGGGTEVEFKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号20
480C8キメラ軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQTPSSVSAAVGGTVTINCQASESISSWLAWYQQKPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRTYVNAFGGGTEVEFK
配列番号21
480C8キメラ重鎖全長核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACGCCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTAATAGTAAGAACATTTGGGGCCAAGGCACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号22
480C8キメラ重鎖可変重鎖核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACGCCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTAATAGTAAGAACATTTGGGGCCAAGGCACCCTGGTCACCGTCTCGAGC
配列番号23
480C8キメラ重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAINSKNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号24
480C8キメラ重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAINSKNIWGQGTLVTVSS
配列番号25
295E9キメラ軽鎖全長核酸配列
GATGTCGTGATGACCCAGACTCCAGCCTCCGTGGAGGCAGCTGTGGGAGGCACAGTCACAATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAGACCAGGGCAGCCTCCCAAACTCCTGATCTACGAAGCATCCAAACTGGCGTCTGGGGTCCCATCGCGGTTCAAAGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTAGTTATGTAAATGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号26
295E9キメラ軽鎖可変軽鎖核酸配列
GATGTCGTGATGACCCAGACTCCAGCCTCCGTGGAGGCAGCTGTGGGAGGCACAGTCACAATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAGACCAGGGCAGCCTCCCAAACTCCTGATCTACGAAGCATCCAAACTGGCGTCTGGGGTCCCATCGCGGTTCAAAGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAGGCTATTTTTATTTTATTAGTCGTAGTTATGTAAATGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA
配列番号27
295E9キメラ軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQTPASVEAAVGGTVTINCQASESISSWLAWYQQRPGQPPKLLIYEASKLASGVPSRFKGSGSGTEFTLTISDLECADAATYYCQGYFYFISRSYVNAFGGGTEVVVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号28
295E9キメラ軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQTPASVEAAVGGTVTINCQASESISSWLAWYQQRPGQPPKLLIYEASKLASGVPSRFKGSGSGTEFTLTISDLECADAATYYCQGYFYFISRSYVNAFGGGTEVVVK
配列番号29
295E9キメラ重鎖全長核酸配列
CAGTCACTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGTAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATTAATTACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAAGAACATTTGGGGCCCAGGCACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号30
295E9キメラ重鎖可変重鎖核酸配列
CAGTCACTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGTAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATTAATTACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAAGAACATTTGGGGCCCAGGCACCCTGGTCACCGTCTCGAGC
配列番号31
295E9キメラ重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDINYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSKNIWGPGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号32
295E9キメラ重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDINYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSKNIWGPGTLVTVSS
配列番号33
480A7キメラ軽鎖全長核酸配列
GATGTCGTGATGACCCAGACTCCAGCCTCCGTGGAGGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAGACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAGGGCTATTTTTATTTTATTAGTCGTAGTTATGTAAATGCTTTCGGCGGAGGGACCGAGGTGGTGTTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号34
480A7キメラ軽鎖可変軽鎖核酸配列
GATGTCGTGATGACCCAGACTCCAGCCTCCGTGGAGGCAGCTGTGGGAGGCACAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAGACCAGGGCAGCCTCCCAAGCTCCTGATCTACGAAGCATCCAAACTGGCATCTGGGGTCCCATCGCGGTTCAGTGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAGGGCTATTTTTATTTTATTAGTCGTAGTTATGTAAATGCTTTCGGCGGAGGGACCGAGGTGGTGTTCAAA
配列番号35
480A7キメラ軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQTPASVEAAVGGTVTINCQASESISSWLAWYQQRPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRSYVNAFGGGTEVVFKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号36
480A7キメラ軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQTPASVEAAVGGTVTINCQASESISSWLAWYQQRPGQPPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQGYFYFISRSYVNAFGGGTEVVFK
配列番号37
480A7キメラ重鎖全長核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAAGAACATTTGGGGCCCGGGCACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号38
480A7キメラ重鎖可変重鎖核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGACCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAAGAACATTTGGGGCCCGGGCACCCTGGTCACCGTCTCGAGC
配列番号39
480A7キメラ重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSKNIWGPGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号40
480A7キメラ重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMTSLTAEDSATYFCARDGGSSAITSKNIWGPGTLVTVSS
配列番号41
485H6キメラ軽鎖全長核酸配列
GATGTCGTGATGACCCAGACTCCAGCCTCCGTGTCTGAACCTGTGGGAGGCACAGTCACCATCAAGTGCCAGGCCAGTGAGAGCATTAATAGTAATGTAGCCTGGTATCAGCAGAAACCAGGGCAGCGTCCCAAGCTCCTGATCTATGATTCATCCACTCTGGAATCTGGGGTCCCATCGCGGTTCAAAGGCAGTAGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCCGCCACTTACTACTGTCAATGTAGTAGTTATGGTAGTAGTTATGTTGGTGGTTTCGGCGGAGGGACCGAGGTGGTGTTCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号42
485H6キメラ軽鎖可変軽鎖核酸配列
GATGTCGTGATGACCCAGACTCCAGCCTCCGTGTCTGAACCTGTGGGAGGCACAGTCACCATCAAGTGCCAGGCCAGTGAGAGCATTAATAGTAATGTAGCCTGGTATCAGCAGAAACCAGGGCAGCGTCCCAAGCTCCTGATCTATGATTCATCCACTCTGGAATCTGGGGTCCCATCGCGGTTCAAAGGCAGTAGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCCGCCACTTACTACTGTCAATGTAGTAGTTATGGTAGTAGTTATGTTGGTGGTTTCGGCGGAGGGACCGAGGTGGTGTTCAAA
配列番号43
485H6キメラ軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQTPASVSEPVGGTVTIKCQASESINSNVAWYQQKPGQRPKLLIYDSSTLESGVPSRFKGSRSGTEFTLTISDLECADAATYYCQCSSYGSSYVGGFGGGTEVVFKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号44
485H6キメラ軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQTPASVSEPVGGTVTIKCQASESINSNVAWYQQKPGQRPKLLIYDSSTLESGVPSRFKGSRSGTEFTLTISDLECADAATYYCQCSSYGSSYVGGFGGGTEVVFK
配列番号45
485H6キメラ重鎖全長核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGCCCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAAGAACATTTGGGGCCAGGGGACCCTCGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号46
485H6キメラ重鎖可変重鎖核酸配列
CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGTCGACCACGGTGGATCTGAAAATGCCCAGTCTGACAGCCGAGGACTCGGCCACCTATTTCTGTGCCAGAGACGGTGGTTCTTCTGCTATTACTAGTAAGAACATTTGGGGCCAGGGGACCCTCGTCACCGTCTCGAGC
配列番号47
485H6キメラ重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMPSLTAEDSATYFCARDGGSSAITSKNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号48
485H6キメラ重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
QSLEESGGRLVTPGTPLTLTCTVSGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISKTSSTTVDLKMPSLTAEDSATYFCARDGGSSAITSKNIWGQGTLVTVSS
配列番号49
284A10ヒト化軽鎖全長核酸配列
GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号50
284A10ヒト化軽鎖可変軽鎖核酸配列
GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCAATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
配列番号51
284A10ヒト化軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号52
284A10ヒト化軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK
配列番号53
284A10ヒト化重鎖全長核酸配列
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号54
284A10ヒト化重鎖可変重鎖核酸配列
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC
配列番号55
284A10ヒト化重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号56
284A10ヒト化重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS
配列番号57
299F6ヒト化軽鎖全長核酸配列
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTAGTTATGTAAATGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号58
299F6ヒト化軽鎖可変軽鎖核酸配列
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTAGTTATGTAAATGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
配列番号59
299F6ヒト化軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DIQMTQSPSTLSASVGDRVTITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRSYVNAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号60
299F6ヒト化軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DIQMTQSPSTLSASVGDRVTITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRSYVNAFGGGTKVEIK
配列番号61
299F6ヒト化重鎖全長核酸配列
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAACTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号62
299F6ヒト化重鎖可変重鎖核酸配列
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAACTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC
配列番号63
299F6ヒト化重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
EVQLVESGGGLVQPGGSLRLSCAASGFTISSNAMSWVRQAPGKGLEWIGVITGRDITYYANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号64
299F6ヒト化重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
EVQLVESGGGLVQPGGSLRLSCAASGFTISSNAMSWVRQAPGKGLEWIGVITGRDITYYANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS
配列番号65
480C8ヒト化軽鎖全長核酸配列
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
配列番号66
480C8ヒト化軽鎖可変軽鎖核酸配列
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA
配列番号67
480C8ヒト化軽鎖全長アミノ酸配列. ヒトカッパ定常領域は下線
DIQMTQSPSTLSASVGDRVTITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNAFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
配列番号68
480C8ヒト化軽鎖可変軽鎖アミノ酸配列. 相補性決定領域は下線
DIQMTQSPSTLSASVGDRVTITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNAFGGGTKVEIK
配列番号69
480C8ヒト化重鎖全長核酸配列
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTAATAGTAAGAACATTTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT
配列番号70
480C8ヒト化重鎖可変重鎖核酸配列
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAATCGACCTCAGTAGCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTAATAGTAAGAACATTTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC
配列番号71
480C8ヒト化重鎖全長アミノ酸配列. ヒトガンマ-1定常領域は下線
EVQLVESGGGLVQPGGSLRLSCAASGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAINSKNIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
配列番号72
480C8ヒト化重鎖可変重鎖アミノ酸配列. 相補性決定領域は下線
EVQLVESGGGLVQPGGSLRLSCAASGIDLSSNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAINSKNIWGQGTLVTVSS
Claims (24)
- ヒトCD3に対する結合特異性を有する単離されたモノクローナル抗体(mAb)又はその抗原結合断片であって、
前記単離された抗体(mAb)又は抗原結合断片は、配列番号73のアミノ酸配列を含む軽鎖CDR1、配列番号74のアミノ酸配列を含む軽鎖CDR2、配列番号75のアミノ酸配列を含む軽鎖CDR3、配列番号76のアミノ酸配列を含む重鎖CDR1、配列番号77のアミノ酸配列を含む重鎖CDR2、及び配列番号78のアミノ酸配列を含む重鎖CDR3を含む、
単離されたmAb又はその抗原結合断片。 - T細胞活性化の増強、抗体応答の刺激、又は免疫抑制細胞の抑制機能の逆転が可能である、請求項1に記載の単離されたmAb又は抗原結合断片。
- 前記T細胞活性化の増強が、T細胞増殖、IFN-γ及び/又はIL-2分泌、又はそれらの組み合わせを含む、請求項2に記載の単離されたmAb又は抗原結合断片。
- 前記免疫抑制細胞が制御性T細胞を含む、請求項2又は3に記載の単離されたmAb又は抗原結合断片。
- 前記単離されたmAbが、ヒト化抗体、キメラ抗体、又は組換え抗体である、請求項1~4のいずれかに記載の単離されたmAb又はその抗原結合断片。
- 前記単離されたmAbが、IgGである、請求項1~5のいずれかに記載の単離されたmAb又はその抗原結合断片。
- 前記抗原結合断片が、Fv、Fab、F(ab')2、scFV、又はscFV2断片である、請求項1~6のいずれかに記載の単離されたmAb又はその抗原結合断片。
- 前記単離されたmAbが、二重特異性抗体、三重特異性抗体、又は多重特異性抗体を含む、請求項1~7のいずれかに記載の単離されたmAb又はその抗原結合断片。
- 請求項1~8のいずれかに記載の単離されたmAb又は抗原結合断片をコードする単離された核酸。
- 請求項9に記載の単離された核酸を含む、発現ベクター。
- 請求項9に記載の核酸を含む宿主細胞であって、原核細胞又は真核細胞である、宿主細胞。
- 抗体が生産されるように請求項11に記載の宿主細胞を培養する工程を含む、抗体の生産方法。
- 請求項1~8のいずれかに記載の単離されたmAb又はその抗原結合断片及び薬物単位を含む免疫複合体であって、
前記薬物単位は、リンカーを介して、単離されたmAb又は抗原結合断片に連結され、且つ
前記リンカーは、エーテル結合、アミン結合、アミド結合、ジスルフィド結合、イミド結合、スルホン結合、リン酸結合、又はそれらの組み合わせから選択される共有結合を含む、
免疫複合体。 - 前記薬物単位が、細胞毒性剤、免疫調節剤、造影剤、又はそれらの組み合わせを含む、請求項13に記載の免疫複合体。
- 前記細胞毒性剤が、チューブリン結合剤、DNAインターカレーター、DNAアルキレーター、酵素阻害剤、免疫調節因子、代謝拮抗剤、放射性同位体、又はそれらの組み合わせの一群から選ばれる、増殖阻害剤又は化学療法剤から選択される、請求項14に記載の免疫複合体。
- 前記細胞毒性剤がカリケアマイシン、オゾガマイシン、モノメチルオーリスタチンE、エムタンシン、それらの誘導体又は組み合わせから選択される、請求項14又は15に記載の免疫複合体。
- 前記免疫調節剤が、免疫細胞、T細胞、NK細胞、B細胞、マクロファージ、又は樹状細胞を活性化又は抑制する、請求項14~16のいずれかに記載の免疫複合体。
- 前記造影剤が、放射性核種、蛍光剤、量子ドット、又はそれらの組み合わせであってもよい、請求項14~17のいずれかに記載の免疫複合体。
- 請求項1~8のいずれかに記載の単離されたmAb又はその抗原結合断片、及び薬学的に許容される担体を含む、医薬組成物。
- カリケアマイシン、抗有糸分裂剤、毒素、放射性同位元素、治療剤、またはそれらの組み合わせの一群から選ばれる、化学療法剤、増殖阻害剤、細胞毒性剤をさらに含む、請求項19に記載の医薬組成物。
- 請求項13に記載の免疫複合体、及び薬学的に許容される担体を含む、医薬組成物。
- 請求項1~8のいずれかに記載の単離されたmAb又はその抗原結合断片の有効量を含む、癌を有する対象の治療用の医薬組成物。
- 前記治療は、有効量の治療薬を同時投与する工程を含み、前記治療薬が抗体、化学療法薬、酵素、又はそれらの組み合わせを含む、請求項22に記載の医薬組成物。
- 前記対象がヒトである、請求項22又は23に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762551032P | 2017-08-28 | 2017-08-28 | |
US62/551,032 | 2017-08-28 | ||
PCT/US2018/039143 WO2019045856A1 (en) | 2017-08-28 | 2018-06-22 | ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020533970A JP2020533970A (ja) | 2020-11-26 |
JP7164596B2 true JP7164596B2 (ja) | 2022-11-01 |
Family
ID=65527572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020511453A Active JP7164596B2 (ja) | 2017-08-28 | 2018-06-22 | 抗cd3抗体とその作製及び使用方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11535667B2 (ja) |
EP (1) | EP3676294A4 (ja) |
JP (1) | JP7164596B2 (ja) |
CN (1) | CN110799538B (ja) |
WO (1) | WO2019045856A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
WO2023169419A1 (en) * | 2022-03-09 | 2023-09-14 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-cd3 antibodies and uses thereof |
WO2024012513A1 (en) * | 2022-07-13 | 2024-01-18 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012504970A (ja) | 2008-10-10 | 2012-03-01 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Tcr複合体免疫治療 |
JP2015521032A (ja) | 2012-04-20 | 2015-07-27 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd3結合ポリペプチド |
WO2016055592A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
JP2016520600A (ja) | 2013-05-28 | 2016-07-14 | ヌマブ アクチェンゲゼルシャフト | 新規抗体 |
WO2016112870A1 (en) | 2015-01-16 | 2016-07-21 | Tse-Wen Chang | Molecular constructs with targeting and effector elements |
JP2017523176A (ja) | 2014-07-25 | 2017-08-17 | シトムクス セラピューティクス,インコーポレイティド | 抗−cd3抗体、活性化可能抗−cd3抗体、多重特異的抗−cd3抗体、多重特異的活性化可能抗−cd3抗体、及びそれらの使用方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CN1195779C (zh) * | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
EA010350B1 (ru) * | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Антитела против cd3 и способы их применения |
EP2714733B1 (en) * | 2011-05-21 | 2019-01-23 | MacroGenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
SG10202003171TA (en) * | 2015-01-08 | 2020-05-28 | BioNTech SE | Agonistic tnf receptor binding agents |
EP3645048A4 (en) * | 2017-06-25 | 2021-06-16 | Systimmune, Inc. | MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF |
WO2019005641A1 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF |
US11649286B2 (en) * | 2017-06-25 | 2023-05-16 | Systimmune Inc. | Tri-specific antibodies |
-
2018
- 2018-06-22 WO PCT/US2018/039143 patent/WO2019045856A1/en unknown
- 2018-06-22 EP EP18850111.8A patent/EP3676294A4/en active Pending
- 2018-06-22 CN CN201880038306.2A patent/CN110799538B/zh active Active
- 2018-06-22 JP JP2020511453A patent/JP7164596B2/ja active Active
- 2018-06-22 US US16/615,109 patent/US11535667B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012504970A (ja) | 2008-10-10 | 2012-03-01 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Tcr複合体免疫治療 |
JP2015521032A (ja) | 2012-04-20 | 2015-07-27 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd3結合ポリペプチド |
JP2016520600A (ja) | 2013-05-28 | 2016-07-14 | ヌマブ アクチェンゲゼルシャフト | 新規抗体 |
JP2017523176A (ja) | 2014-07-25 | 2017-08-17 | シトムクス セラピューティクス,インコーポレイティド | 抗−cd3抗体、活性化可能抗−cd3抗体、多重特異的抗−cd3抗体、多重特異的活性化可能抗−cd3抗体、及びそれらの使用方法 |
WO2016055592A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
WO2016112870A1 (en) | 2015-01-16 | 2016-07-21 | Tse-Wen Chang | Molecular constructs with targeting and effector elements |
Non-Patent Citations (1)
Title |
---|
Immunotherapy (2016) Vol.8, No.8, pp.889-906 |
Also Published As
Publication number | Publication date |
---|---|
US20200157217A1 (en) | 2020-05-21 |
WO2019045856A1 (en) | 2019-03-07 |
US11535667B2 (en) | 2022-12-27 |
EP3676294A1 (en) | 2020-07-08 |
CN110799538B (zh) | 2023-08-01 |
EP3676294A4 (en) | 2021-12-22 |
CN110799538A (zh) | 2020-02-14 |
JP2020533970A (ja) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7323513B2 (ja) | 抗4-1bb抗体とその作製及び使用方法 | |
JP7490109B2 (ja) | 抗pd-1抗体とその作製及び使用方法 | |
WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
JP7164596B2 (ja) | 抗cd3抗体とその作製及び使用方法 | |
JP2024023249A (ja) | 抗pd-l1抗体とその作製及び使用方法 | |
US20240084026A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение | |
CN115368456A (zh) | 抗pd-1多肽及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200427 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210331 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220527 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220630 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220927 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221020 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7164596 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |